Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase NA 5Phase 2 5Phase EARLY_PHASE1 3Phase 2/3 3Phase 4 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Dexamethasone 13Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Cisplatin 6Carboplatin 6Sodium Chloride 5Ropivacaine 5Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Paclitaxel 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Positron Emission Tomography Computed Tomography × 1 year × Clear all
NCT06479187 2025-11-05

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Brigham and Women's Hospital

Phase 4 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡